JP2022525071A5 - - Google Patents
Info
- Publication number
- JP2022525071A5 JP2022525071A5 JP2021553837A JP2021553837A JP2022525071A5 JP 2022525071 A5 JP2022525071 A5 JP 2022525071A5 JP 2021553837 A JP2021553837 A JP 2021553837A JP 2021553837 A JP2021553837 A JP 2021553837A JP 2022525071 A5 JP2022525071 A5 JP 2022525071A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- cdrs
- domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817749P | 2019-03-13 | 2019-03-13 | |
| US62/817,749 | 2019-03-13 | ||
| PCT/US2020/021783 WO2020185722A2 (en) | 2019-03-13 | 2020-03-10 | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525071A JP2022525071A (ja) | 2022-05-11 |
| JP2022525071A5 true JP2022525071A5 (cg-RX-API-DMAC7.html) | 2023-03-24 |
| JP7581225B2 JP7581225B2 (ja) | 2024-11-12 |
Family
ID=72426465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553837A Active JP7581225B2 (ja) | 2019-03-13 | 2020-03-10 | Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12358986B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3937979A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7581225B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210141539A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113631189B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020234785B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021017892A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132198A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA55316A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021010997A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020185722A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102986821B1 (ko) | 2020-04-22 | 2026-07-06 | 머크 샤프 앤드 돔 엘엘씨 | 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체 |
| TW202241932A (zh) * | 2020-12-23 | 2022-11-01 | 美商默沙東藥廠 | 用於治療自體免疫及發炎性疾病之il-2突變蛋白 |
| EP4286520A4 (en) * | 2021-01-29 | 2025-04-16 | Minghui Pharmaceutical (Hangzhou) Limited | Antigen-binding protein and use thereof |
| IL307494A (en) * | 2021-04-14 | 2023-12-01 | Akeso Pharmaceuticals Inc | Use of antibody in anti-tumor treatment |
| TWI903067B (zh) * | 2021-04-21 | 2025-11-01 | 中國商和鉑醫藥(上海)有限責任公司 | 結合ctla-4的抗體及其用途 |
| KR20230110141A (ko) | 2022-01-14 | 2023-07-21 | 영남대학교 산학협력단 | PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도 |
| EP4522654A1 (en) * | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| KR20260056175A (ko) * | 2023-08-21 | 2026-04-24 | 아게누스 인코포레이티드 | Ctla-4 저해제와 pd-1 저해제의 병용을 이용한 결장직장암의 치료 방법 |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| WO2025240670A2 (en) * | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| CA2698419C (en) | 2007-09-07 | 2019-11-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| ES2826566T3 (es) | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| CN108473565B (zh) | 2015-11-18 | 2022-05-27 | 默沙东公司 | Ctla4结合剂 |
| US10544222B2 (en) | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| US11072657B2 (en) * | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| CN110505882A (zh) | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
| CA3060695A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
-
2020
- 2020-03-10 MA MA055316A patent/MA55316A/fr unknown
- 2020-03-10 US US17/436,857 patent/US12358986B2/en active Active
- 2020-03-10 KR KR1020217032365A patent/KR20210141539A/ko active Pending
- 2020-03-10 JP JP2021553837A patent/JP7581225B2/ja active Active
- 2020-03-10 AU AU2020234785A patent/AU2020234785B2/en active Active
- 2020-03-10 EP EP20770048.5A patent/EP3937979A4/en active Pending
- 2020-03-10 BR BR112021017892A patent/BR112021017892A8/pt unknown
- 2020-03-10 MX MX2021010997A patent/MX2021010997A/es unknown
- 2020-03-10 CN CN202080020847.XA patent/CN113631189B/zh active Active
- 2020-03-10 WO PCT/US2020/021783 patent/WO2020185722A2/en not_active Ceased
- 2020-03-10 CA CA3132198A patent/CA3132198A1/en active Pending
-
2025
- 2025-06-03 US US19/226,799 patent/US20250289890A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11718681B2 (en) | Anti-SIRP α antibodies | |
| US11851495B2 (en) | TRAILR2 CDH17 binding molecules for the treatment of cancer | |
| JP2021531764A5 (cg-RX-API-DMAC7.html) | ||
| CN115551889A (zh) | 抗cd73抗体及其用途 | |
| JP2019500891A5 (cg-RX-API-DMAC7.html) | ||
| JP2019500892A5 (cg-RX-API-DMAC7.html) | ||
| JP2025506318A (ja) | 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用 | |
| JP7581225B2 (ja) | Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法 | |
| US20220204644A1 (en) | Combination of her2 antibodies | |
| JP2025517737A5 (cg-RX-API-DMAC7.html) | ||
| US12521446B2 (en) | Anti-CEACAM5 antibody drug conjugates | |
| US20240150480A1 (en) | Binding molecules for the treatment of cancer | |
| RU2021129575A (ru) | Способы комбинированного лечения злокачественных новообразований, включающие средства, блокирующие ctla-4 и pd-1 | |
| JP2024508597A5 (cg-RX-API-DMAC7.html) | ||
| RU2024116190A (ru) | Антитело против cd73 и его применение | |
| IL321672A (en) | Anti-pdl1/vegf antibodies and methods of use |